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Cohort studies and Relative risks
Richard Ssekitoleko
Objectives
• Define a cohort study and the steps for the study
• Understand the populations in a cohort study
• Understand timing in a cohort study and the difference between 
retrospective, prospective and ambi-directional cohort studies
• Understand the selection of the cohort population and the collection 
of exposure and outcome data
• Understand the sources of bias in a cohort study
• Understand the calculation and interpretation of the relative risk
• Understand use of the new-castle Ottawa quality assessment score 
for cohort studies
Hierarchy of Evidence
Study type
Observational Interventional
Descriptive Experiment
Ecological Randomised Controlled Trial
Cross-sectional
Case-control
Cohort
Study designs and the basic principles
• Randomised controlled trial
• Cohort study( Also called Longitudinal, follow up or Incidence study)
• Case-control study
• Cross-sectional study
• Ecological study
Cohort studies
• Observational study type
• Steps in a cohort study
• Define the target population
• Get a sample of the target 
population
• Identify the exposure status of the 
sampled members
• Follow up the members over time 
to identify new(Incident cases) of 
the disease (outcome)
• Compare the risk of the outcome in 
those who are exposed at baseline 
to those who are not exposed(Risk 
Ratio)
Populations studied in Cohort studies
• Open/Dynamic cohort
• Individuals may enter or leave at anytime
• losses may occur
• Defined by changeable characteristic
• Measure incidence rate
• Fixed Cohort
• Irrevocable event
• Does not gain members/Losses may occur
• Measure incidence rate
• Closed cohort
• Irrevocable event
• Does not gain members; no losses occur
• Measure cumulative incidence
Timing of cohort 
studies
• Events in a cohort study 
defined by 3 terms
• Prospective/ concurrent: Meaning to 
look forward in time
• Retrospective: Meaning to look back 
in time
• Ambi directional: Meaning to look 
both ways
BMJ Glob Health
2017;2:e000344. doi:10.1136/
bmjgh-2017-000344
Retrospective cohort example
• Derivation and validation of a universal vital assessment 
score
• Methods: Pooled data from hospital based cohort studies 
from 2009 to 2015
• Analysis involved 5573 patients
• Exposure: Baseline UVA score
• Outcome: Inpatient mortality 996(17.3%)
• Temporal association between exposure and outcome clear
• By time study occurred both exposures and outcomes had 
occurred 
• Lots of missing data with imputation          Information bias
• 2829 (50.8%) were female.
• Median (IQR) age was 36 (27–49) years
• The UVA score included points for temperature, heart and respiratory rates, 
systolic blood pressure, oxygen saturation, GCS and HIV serostatus.
• The UVA score had an area under the receiver operating characteristic curve 
(AUC) of 0.77 (95% CI 0.75 to 0.79)
• UVA score Outperformed other scoring systems (MEWS and qSOFA)
• UVA score could help with triage decisions in the study settings

Hypoglycemia at admission is associated with in-hospital mortality 
in Ugandan patients with severe sepsis 
Richard Ssekitoleko, MBChB, MMed; Shevin T. Jacob, MD, MPH; Patrick Banura, MBChB, MPH; 
Relana Pinkerton, PhD; David B. Meya, MBChB, Mmed; Steven J. Reynolds, MD, MPH; 
Nathan Kenya-Mugisha, MBChB; Harriet Mayanja-Kizza, MBChB, MS; Rose Muhindo, MBChB, MMed; 
Sanjay Bhagani, MBBS; W. Michael Scheid, MD; Christopher C. Moore, MD, FACP 
Grit Care Med 2011 Vol. 39, No. 1 0 
Prospective cohort example
• Prospective observational study on patients with Sepsis 
in 3 Ugandan hospitals.
• Analysis involved 418 admitted patients
• Exposure:  Admission blood glucose concentration
• Outcome:   In hospital mortality 113(27%)
• Measure of association: Hazard ratio
• Results: Significantly higher rates of mortality in patients 
with hypoglycemia: HR 95% CI 1.9(1.1-3.3)
Table 3. Univariate predictors of survival meeting <0.30 criteria and final multivariate model results using Cox regression 
Hazard Ratio (95% Confidence Interval) and p 
Outcome Survived Died Univariate p Multivariate p 
Admission glucose concentration, n (%) 
Euglycemia (4.4-6.1 mmoi!L) 113 (80.7) 27 (19.3) 
Hypoglycemia ( < 4.4 mmoVL) 44 (64.7) 24 (35.3) 2.0 (1.2-3.6) .013 1.9 (1.1-3.3) .03 
Hyperglycemia (> 6.1 mmoVL) 148 (70.5) 62 (29.5) 1.5 (0.96-2.4) .08 1.6 (0.97-2.5) .07 
AMS,n(%) 
NoAMS 274 (77.6) 79 (22.4) 
AMS 31 (47.7) 34 (52.3) 2.5 (1.6-3.7) < .001 2.2 (1.5-3.4) < .001 
White blood cell count, n (%) 
> 4,000 to < 12,000 cells/I-LL 162 (79.8) 41 (20.2) 
< 4,000 or > 12,000 cells/I-LL 136 (67.0) 67 (33.0) 1.7 (1.1-2.4) .01 1.7 (1.1-2.5) .013 
Heart rate, n (%) 
:S:90 beats/min 18(85.7) 3 (14.3) 
> 90 beats/min 286 (72.4) 109 (27.6) 1.9 (0.60-6.0) .27 Not significant 
Bacteremia or fungemia 
Negative 248 (74.7) 84 (25.3) 
Positive 57 (66.3) 29 (33.7) 1.3 (0.88-2.0) .18 Not significant 
Platelets, n (%) 
:2: 100,000 cells/I-LL 245 (79.5) 63 (20.5) 
< 100,000 cells/I-LL 48 (52.2) 44 (47.8) 2.4 ( 1.6-3.5) < .001 1.8 (1.2- 2. 7) .007 
Hospital site,0 n (%) 
Mulago or Masaka 249 (77.3) 73 (22.7) 
Mbarara 56 (58.3) 40 (41.7) 2.4 ( 1.6-3.5) < .001 1.8 (1.2- 2.9) .004 
• Temporal association between admission blood glucose and mortality 
clear
• Researchers identified baseline exposures and then followed up 
patients (Prospective observational study)
Selecting the cohort population
• Based on study hypothesis
• Guided by the exposure to be studied e.g smokers vs non smokers
• May be population based cohort based on common exposures e.g
smoking, alcohol consumption, exercise and common chronic 
illnesses
• May be exposure based e.g occupational groups such as road builders
Collection of Exposure and Outcome data
• Study outcomes have not occurred at the beginning of the cohort 
follow up period.
• Exposures of interest may vary during the study period.
• May be present at the beginning
• May occur during the study
• May stop during the study period
• Temporal association between exposure and outcome is clear
Study population
• At the beginning of follow up all cohort members should be alive not 
have the outcome of interest
• All members should be at risk of getting the outcome of interest
• E.g In a study of women involving an outcome of uterine ca, one cannot 
include women who had a hysterectomy at baseline
Comparison populations in cohort studies
• Single cohort
• Members of a single population are classified by levels of 
exposure
• Comparison group is unexposed or less exposed group
• Need to account for confounding factors
• Common exposures: alcohol, smoking, exercise
• Double cohort
• Involves an exposed population and an unexposed population 
• Comparison group may be the general population
Sources of exposure information
• Data may be collected routinely during 
follow up period
• Sources of data
• Participant interviews
• Monitoring data from home or workplace
• Laboratory monitoring
• Medical records
Outcome data in a cohort 
study
• Reports of symptoms and signs
• Medical assessment results
• Medical records
• Disease registry results
• Medical examination results
• Death certificates
Follow up in a cohort study
• All participants need to be tracked throughout the study
• To get their true outcome
• To get their person time contribution to the study
• Loss to follow up is a form of bias and reduces validity of results
• Decreased sample size reducing ability of the study to detect an association if 
present
• Those lost to follow up may differ in important ways from those who stay
• May occur due to death, change of residence, migration or 
participant decision to stop taking part in the study
Minimizing loss to follow up in a cohort study
• Explain need to follow up with participants at start
• Get contact details for participant, friends, relatives or physician
• Maintain regular follow up (Mail, phone or personal contact)
• Follow up on non responses and disappearances promptly
• Offer incentives for follow up e.g transport refund
Analysis in a cohort study
• Need to calculate incidence in the exposed and 
unexposed groups
• May calculate cumulative incidence or incidence 
density rate depending on the available 
information
• Comparing incidence in the exposed and 
unexposed groups will enable estimation of the 
relative risk
RISK of outcome occurrence
in exposed
RISK of outcome occurrence
in unexposed
=
Risk Ratio (RR)
RR > 1 suggests exposure predisposes to outcome
RR < 1 suggests exposure protects against outcome
RR = 1 is null and indicates no association between exposure and 
outcome
Risk Ratio (relative risk)
Interpreting the relative risk
• Gives the strength of association between the exposure and outcome
• May not be causal
• Could be explained by random error, confounding or bias 
• May represent the cumulative incidence ratio or the incidence density 
ratio depending on how it is calculated
Risk Ratio Calculations
If, after follow up, the following is seen:
 Yes No Total 
Yes d1 h1 n1 = d1+ h1 
No d0 h0 n0 = d0+ h0 
Total d=d1+ d0 h=h1+ h0 n=d+h  
 
 
Disease
Then, Simple Cumulative incidence(risk ratio(RR) =
0
0
1
1
n
d
n
d
unexposedin risk 
exposedin risk 
=
Simple Cumulative incidence example
• The table below summarizes a population of 1000 subjects with respect to a 
particular disease D broken down by sex
• What is the relative risk of getting the disease associated with being a man as 
opposed to being a woman?
Relative risk= Risk of disease in men/Risk in 
women=(140/200)/(180/800)=0.7/0.225=3.1
 
Disease 
D D¯ Total 
 
Men 140 60 200 
Women 180 620 800 
Total  320 680 1000 
 
 
Odds ratios and risk ratios
• How do you interpret the relative risk?
The risk of getting the disease in males is 3.1 times the risk of getting the disease in 
females
• What is the odds ratio for the disease among men as opposed to women?
Odds of the disease in men: Odds=Risk of disease in men/risk of no disease in men= 
(140/200)/(60/200)=0.7/0.3=2.3
Odds of the disease among women: Probability of disease in women/Probability of no 
disease  (180/800)/(620/800)=0.29
The odds ratio for disease associated with being a man as opposed to a 
woman. Odds ratio= Odds in men/Odds in women= 2.3/0.29=7.93
• In which type of study is the odds ratio the preferred measure of 
association?
• Compare the risk ratio to the odds ratio. What do you conclude?
Incidence density 
• Person-time at risk
• Length of time for each individual that they are in the population at risk
• Sum of person time for each individual during their stay in study is the total person-
time
• When a person is no longer at risk, they no longer contribute to person time 
e.g when they get the outcome
• Incidence density
• Rate of occurrence of new cases of disease during person time of observation in a 
population at risk of getting the disease
• Numerator =Number of new cases of disease
• Denominator=Total person time of observation in population at risk
• A rate and the units are Inverse time (1/time)
Incidence density ratio
• Incidence density ratio= Incidence density in exposed group/Incidence density 
in unexposed group
• Incidence density ratio= (C/A)/(B/D)
Total person 
time of 
observation
Number of 
persons 
with 
outcome
Incidence 
density
Exposed 
group
A C C/A
Unexposed 
group
B D B/D
Incidence rate ratio example
A study examined mortality among homeless shelter residents in New York City 
from 1987 to 1994.  There were 15 deaths observed among women aged 25-34, 
with 728 person-years of observation.  Among men aged 25-34, 31 deaths were 
observed, with 1988 person-years of observation. (Am J Public Health. 1999 
Apr;89(4):529-34).
Death Person-time
Women 15 728
Men 31 1988
• The measure of relative risk appropriate for this data is the Incidence density 
ratio. 
• Incidence density =number of new cases/total person time at risk
• The relative risk of mortality among women aged 18-24 compared to men aged 
18-24 is the incidence density ratio and is given by:
Incidence density women/Incidence density men
=(15/728)/(31/1988)=1.32
• Interpretation
• The rate of mortality among women was 1.32 times the rate of mortality among men in New 
York City between 1987 and 1994. 
• What is the difference between the Incidence density ratio and the cumulative 
incidence ratio?
• How do we get the person time?
Limitations of cohort studies
• Measurement error (A form of information bias)
• Commonly errors in exposure measurement
• Errors in outcome assessment(People may die from competing risks, actual onset of the disease 
may be missed) 
• Confounding- Occurs when a factor is causally associated with both the outcome 
and exposure under study
• Selection bias (To the different groups and loss to follow up)
• Loss to follow-up (A form of selection bias)
• If it is related to the exposure or outcome of interest
• May be differential or non-differential
Loss to follow-up
• A problem with cohort studies is loss to follow-up
• Loss to follow-up may be non-differential i.e. not related to exposure and 
outcome 
• Or differential i.e. is related to exposure and/or outcome. e.g. subjects with 
poor education who contract HIV die very quickly and do not present to 
health centres or hospitals. Affects the measure of effect
7.36
Cohort Studies
Advantages
• Clear temporal relationship: between 
exposure and outcome (Compare cross 
sectional studies)
• Good for rare exposures
• Can evaluate multiple effects of an exposure 
• Can minimise biases in  exposure 
measurement
• Directly measures disease incidence or risk
Disadvantages
• Usually expensive and Time consuming 
(Prospective)
• Poor information on exposures and other key 
variables (Retrospective)
• Inefficient for disease with long induction 
and latent periods(Prospective)
• Bias/ confounding 
• Changes over time can affect exposure and 
disease classification
Critical review 
for cohort 
studies
J Korean Med Assoc. 2011 
Apr;54(4):419-429.
https://doi.org/10.5124/jkma.20
11.54.4.419
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